Buch

Beschreibung

The focus on HIV therapy has changed during the last ten years. Long-term treatment of HIV infection is now the norm in industrialised nations because to an expanding selection of effective, practical novel medicines and co-formulations. Because of this, maintaining the efficacy of the treatment has become dependent on tolerance and side-effect control.
The majority of those who are infected do not have access to HIV and AIDS medications and therapies because anti-retroviral drugs are pricey. Antiviral medications are linked to a wide variety of adverse responses, metabolic issues, and toxicity, and research is ongoing to reduce the negative effects of currently available medications.